Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
Castle Biosciences (Nasdaq: CSTL) announced that its Chief Operating Officer, Kristen Oelschlager, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by the Arizona Bioindustry Association (AZBio). Oelschlager, a registered nurse with over 15 years of experience in clinical nursing, operations services, and research, is recognized for her significant contributions to the progression of the bioscience industry in Arizona.
As a co-founder of Castle Biosciences in 2008, Oelschlager has played a important role in the company's growth and success. Castle Biosciences specializes in innovative testing solutions to guide treatment decisions for cancer patients. The award will be presented at the AZBio Awards on September 18, 2024, at the Phoenix Convention Center.
Castle Biosciences (Nasdaq: CSTL) ha annunciato che il suo Chief Operating Officer, Kristen Oelschlager, è stata nominata Leader dell'Anno 2024 Jon W. McGarity nel settore delle bioscienze in Arizona dall'Associazione delle Bioindustrie dell'Arizona (AZBio). Oelschlager, infermiera registrata con oltre 15 anni di esperienza nella cura clinica, nei servizi operativi e nella ricerca, è riconosciuta per i suoi significativi contributi al progresso dell'industria bioscientifica in Arizona.
Come co-fondatrice di Castle Biosciences nel 2008, Oelschlager ha svolto un ruolo importante nella crescita e nel successo dell'azienda. Castle Biosciences si specializza in soluzioni di test innovative per guidare le decisioni terapeutiche per i pazienti oncologici. Il premio sarà consegnato agli AZBio Awards il 18 settembre 2024, presso il Phoenix Convention Center.
Castle Biosciences (Nasdaq: CSTL) anunció que su directora de operaciones, Kristen Oelschlager, ha sido nombrada Líder del Año 2024 Jon W. McGarity en Biociencias de Arizona por la Asociación de Bioindustrias de Arizona (AZBio). Oelschlager, enfermera registrada con más de 15 años de experiencia en enfermería clínica, servicios operativos e investigación, es reconocida por sus contribuciones significativas al progreso de la industria de las biosciencias en Arizona.
Como cofundadora de Castle Biosciences en 2008, Oelschlager ha desempeñado un papel importante en el crecimiento y éxito de la empresa. Castle Biosciences se especializa en soluciones de pruebas innovadoras para guiar las decisiones de tratamiento para pacientes con cáncer. El premio se presentará en los AZBio Awards el 18 de septiembre de 2024, en el Centro de Convenciones de Phoenix.
캐슬 바이오사이언스(Castle Biosciences, Nasdaq: CSTL)는 최고 운영 책임자 크리스틴 오엘슈라거(Kristen Oelschlager)가 애리조나 생명산업 협회(AZBio)로부터 2024년 존 W. 맥가리티 애리조나 생명과학 산업 올해의 리더로 선정되었다고 발표했습니다. 오엘슈라거는 15년 이상의 임상 간호, 운영 서비스 및 연구 경험을 가진 등록 간호사로, 애리조나 생명과학 산업의 발전에 중요한 기여를 한 것으로 인정받고 있습니다.
2008년 캐슬 바이오사이언스를 공동 설립한 오엘슈라거는 회사의 성장과 성공에 중요한 역할을 해왔습니다. 캐슬 바이오사이언스는 암 환자의 치료 결정을 안내하기 위한 혁신적인 테스트 솔루션을 전문으로 합니다. 이 상은 2024년 9월 18일 피닉스 컨벤션 센터에서 개최되는 AZBio 시상식에서 수여될 예정입니다.
Castle Biosciences (Nasdaq: CSTL) a annoncé que son directeur des opérations, Kristen Oelschlager, a été nommé Leader de l'Année 2024 Jon W. McGarity en Biosciences de l'Arizona par l'Association des Bioindustries de l'Arizona (AZBio). Oelschlager, infirmière enregistrée avec plus de 15 ans d'expérience en soins cliniques, services opérationnels et recherche, est reconnue pour ses contributions significatives au progrès de l'industrie des biosciences en Arizona.
En tant que co-fondatrice de Castle Biosciences en 2008, Oelschlager a joué un rôle important dans la croissance et le succès de l'entreprise. Castle Biosciences se spécialise dans des solutions de tests innovantes pour guider les décisions de traitement des patients atteints de cancer. Le prix sera remis lors des AZBio Awards le 18 septembre 2024, au Centre de congrès de Phoenix.
Castle Biosciences (Nasdaq: CSTL) gab bekannt, dass ihre Chief Operating Officer, Kristen Oelschlager, von der Arizona Bioindustry Association (AZBio) zur Leaderin des Jahres 2024 Jon W. McGarity im Bereich Biosciences ernannt wurde. Oelschlager, eine eingetragene Krankenschwester mit über 15 Jahren Erfahrung in der klinischen Pflege, Betrieb und Forschung, wird für ihre bedeutenden Beiträge zum Fortschritt der Bioscience-Industrie in Arizona anerkannt.
Als Mitbegründerin von Castle Biosciences im Jahr 2008 hat Oelschlager eine wichtige Rolle im Wachstum und Erfolg des Unternehmens gespielt. Castle Biosciences spezialisiert sich auf innovative Testlösungen zur Unterstützung von Behandlungsentscheidungen für Krebspatienten. Der Preis wird am 18. September 2024 bei den AZBio Awards im Phoenix Convention Center verliehen.
- Recognition of COO Kristen Oelschlager as Arizona Bioscience Leader of the Year, potentially enhancing company reputation
- Acknowledgment of Oelschlager's role in Castle Biosciences' growth trajectory and workplace culture
- None.
“Kristen’s tenacity, thoughtful leadership and passion for people have had an immeasurable influence on Castle’s growth trajectory, our strong workplace culture and the legacy of improved patient care that we are working to build as a company,” said Derek Maetzold, president and chief executive officer of Castle. “It has been an honor to work alongside her for the better part of two decades, and I can think of no person more deserving of this honor.”
“The entirety of Kristen’s professional career has been dedicated to positively impacting the care of patients, first at the bedside as a nurse and now more broadly through her work at Castle Biosciences,” said Joan Koerber-Walker, president and chief executive officer of AZBio. “Kristen’s contributions to the advancement of patient care are helping to re-shape disease management paradigms in
In 2008, Oelschlager joined Maetzold and Toby Juvenal, chief commercial officer, in a new entrepreneurial endeavor as a founder of Castle Biosciences, a company offering innovative testing solutions to guide treatment decisions for patients impacted by cancers. Her diverse background spanning more than 15 years in clinical nursing, operations services and research has provided a unique perspective that has been instrumental in the Company’s ongoing growth and success.
Arizona’s life science community will gather on September 18, 2024, at the
About The Arizona Bioindustry Association, Inc. (AZBio)
For 20 years, the Arizona Bioindustry Association has supported life science innovation and life science innovators in
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916356187/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
Who was named Arizona Bioscience Leader of the Year for 2024?
What is Castle Biosciences (CSTL) known for?
When was Castle Biosciences (CSTL) founded?
When and where will Kristen Oelschlager receive the Arizona Bioscience Leader of the Year award?
